2019 American Transplant Congress
Pneumocystis Prophylaxis in Solid Organ Transplant Recipients at Two Large Transplant Centers from 2015-2016: Why Not Trimethoprim-Sulfamethoxazole?
*Purpose: Trimethoprim-sulfamethoxazole (T/S) is the drug of choice for Pneumocystis jirovecii pneumonia (PJP) prophylaxis (ppx) after solid organ transplant (SOT). Perceived side effects may lead…2019 American Transplant Congress
Impact of a Short Duration, Narrow Spectrum Perioperative Antibiotic Prophylaxis Regimen on Multi-Drug Resistant Surgical Site Infections in Adult Orthotopic Liver Transplantation
*Purpose: There is a paucity of data defining the optimal agent and timing of peri-operative antimicrobial prophylaxis in orthotopic liver transplantation (OLT). The purpose of…2019 American Transplant Congress
Retrospective Evaluation of Dapsone Prophylaxis Complications in Kidney Transplant Recipients
*Purpose: Secondary options for Pneumocystis Jirovecii pneumonia (PJP) prophylaxis in kidney transplant recipients (KTRs) include atovaquone or dapsone. Atovaquone use may be limited by cost/side…2019 American Transplant Congress
Low-Dose Valacyclovir Prophylaxis for Cytomegalovirus Infection in Renal Transplant Recipients with Intermediate Risk
*Purpose: According to recent guidelines ganciclovir or valganciclovir chemoprophylaxis is recommended for all kidney transplantation (KT) recipients (except for D-/R- serology) for preventing cytomegalovirus (CMV)…2018 American Transplant Congress
Impact of Positive Donor Blood Cultures in Liver Transplant Recipients
Emory University Hospital, Atlanta, GA.
The purpose of this study was to describe the bacteremia transmission rate of transplanting livers from donors with positive bacterial blood cultures into liver transplant…2018 American Transplant Congress
Early versus Late Cytomegalovirus Prophylaxis after Kidney Transplant
Duke University Hospital, Durham, NC.
Background: Prophylaxis against cytomegalovirus (CMV) is recommended in high-risk patients (CMV D+/R-) and those who are CMVR+ and getting T-cell depletional therapy. It is unclear…2018 American Transplant Congress
Micafungin Prophylaxis in Liver Transplant Recipients at High Risk for Invasive Fungal Infections
Medstar Georgetown University Hospital, Department of Pharmacy, Washington, DC.
Purpose: This study was conducted to determine the incidence of proven or probable invasive fungal infections in the first 90 days after transplant in high…2018 American Transplant Congress
Increase in Potentially Resistant Non-Aspergillus Molds Isolated in Lung Transplant Recipients after Voriconazole and Posaconazole Prophylaxis
Background: Lung transplant recipients are at higher risk for invasive fungal infections compared to other solid organs transplant patients. Antifungal prophylaxis with mold-active azoles has…2018 American Transplant Congress
Infection Outcomes in Solid Organ Transplant Recipients Receiving Trimethoprim-Sulfamethoxazole as Opposed to Atovaquone for Prophylaxis
Background: Pneumocystis jiroveci pneumonia (PJP) is an important illness amongst solid organ transplant (SOT) recipients. Trimethoprim-sulfamethoxazole (TMP-SMX) is the prophylaxis of choice based on efficacy…2018 American Transplant Congress
Making Sense of Hepatitis B Reactivation Risk in Anti-HBc Antibody (Ab) Positive Liver Transplant Recipients
Background: Limited data exists regarding the rates of reactivation of hepatitis B virus (HBV) in anti-HBc Ab positive orthotopic liver transplant (OLT) recipients. Protocols vary…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 14
- Next Page »